

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1260	(546/226).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:26
L2	1014881	l1 and 1,2-di(cyclic)substituted	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:27
L3	0	l1 and 1,2-dicyclic adj substituted adj benzene	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:28
L4	0	l1 and 1,2-dicyclic	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:28
L5	0	l1 and dicyclic adj substituted adj benzene	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:30
L6	0	l1 and dicyclic and substituted and benzene	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:43
L7	0	l1 and dicyclic and cyclo! and (piperazin! or piperidin!)	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:44
L8	22	l1 and cyclo! and (piperazin! or piperidin!)	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:44
L9	2	l1 and cyclo!.clm. and (piperazin! or piperidin!).clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:45
L10	498	(546/221).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:45
L11	0	l10 and cyclo!.clm. and (piperazin! or piperidin!).clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:46
L12	14	l10 and cyclo! and (piperazin! or piperidin!)	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:46
L13	2	l10 and cyclo!.clm. and (piperazin! or piperidin!)	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:47
L14	477	(546/225).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:47
L15	1	l14 and cyclo!.clm. and (piperazin! or piperidin!).clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:47

EAST Search History

L16	160	(546/228).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:48
L17	1	l16 and cyclo!.clm. and (piperazin! or piperidin!).clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:48
L18	544	(544/392).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:48
L19	1	l18 and cyclo!.clm. and (piperazin! or piperidin!).clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:49
L20	217	(544/395).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:49
L21	0	l20 and cyclo!.clm. and (piperazin! or piperidin!).clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:49
L22	1	l20 and cyclo! and (piperazin! or piperidin!).clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:50
L23	581	(514/255.03).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:50
L24	4	l23 and cyclo!.clm. and (piperazin! or piperidin!).clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:51
L25	2284	(514/317).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:51
L26	23	l25 and cyclo!.clm. and (piperazin! or piperidin!).clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:51
L27	0	l25 and cyclo!.clm. and (piperazin! or piperidin!).clm. and dicyclic	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:52
L28	0	l25 and cyclo!.clm. and (piperazin! or piperidin!).clm. and di-cyclic	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:52
L29	0	l25 and cyclo! and (piperazin! or piperidin!).clm. and di-cyclic	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:52
L30	0	l25 and cyclo! and (piperazin! or piperidin!) and di-cyclic	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:52

EAST Search History

L31	7	l25 and cyclo!.clm. and (piperazin! and piperidin!).clm.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/28 12:53
-----	---	---	------------------------------	----	-----	------------------

50613257

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 18	CA/CAPplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	4	DEC 18	CA/CAPplus patent kind codes updated
NEWS	5	DEC 18	MARPAT to CA/CAPplus accession number crossover limit increased to 50,000
NEWS	6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	7	DEC 27	CA/CAPplus enhanced with more pre-1907 records
NEWS	8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	9	JAN 16	CA/CAPplus Company Name Thesaurus enhanced and reloaded
NEWS	10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	12	JAN 22	CA/CAPplus updated with revised CAS roles
NEWS	13	JAN 22	CA/CAPplus enhanced with patent applications from India
NEWS	14	JAN 29	PHAR reloaded with new search and display fields
NEWS	15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	19	FEB 26	MEDLINE reloaded with enhancements
NEWS	20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	23	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	24	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	25	MAR 16	CASREACT coverage extended
NEWS	26	MAR 20	MARPAT now updated daily
NEWS	27	MAR 22	LWPI reloaded
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

Erich Leeser

50613257

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:57:30 ON 28 MAR 2007

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:58:03 ON 28 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAR 2007 HIGHEST RN 928296-91-7

DICTIONARY FILE UPDATES: 27 MAR 2007 HIGHEST RN 928296-91-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\new10581591.str

L1 STRUCTURE UPLOADED

=> s l1

Erich Leeser

50613257

SAMPLE SEARCH INITIATED 10:58:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 592574 TO ITERATE

0.3% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 11808425 TO 11894535
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.45 0.66

FILE 'REGISTRY' ENTERED AT 10:58:24 ON 28 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAR 2007 HIGHEST RN 928296-91-7
DICTIONARY FILE UPDATES: 27 MAR 2007 HIGHEST RN 928296-91-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\new10581591.str

L3 STRUCTURE UPLOADED

=> s l3
SAMPLE SEARCH INITIATED 10:58:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 592574 TO ITERATE

0.3% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**

Erich Leeser

50613257

PROJECTED ITERATIONS: 11808425 TO 11894535
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> s l3 full

FULL SEARCH INITIATED 10:58:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 11844599 TO ITERATE

2.8% PROCESSED	328261 ITERATIONS	5 ANSWERS
5.9% PROCESSED	696865 ITERATIONS	199 ANSWERS
7.5% PROCESSED	888826 ITERATIONS	203 ANSWERS
8.4% PROCESSED	1000000 ITERATIONS	203 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.59

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**

PROJECTED ITERATIONS: 11844599 TO 11844599
PROJECTED ANSWERS: 2257 TO 2551

L5 203 SEA SSS FUL L3

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
173.00	173.66

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 11:00:18 ON 28 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Mar 2007 VOL 146 ISS 14
FILE LAST UPDATED: 27 Mar 2007 (20070327/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l5

L6 5 L5

=> s l5 full

Erich Leeser

50613257

L7

5 L5

=> d ibib abs hitstr tot

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1280877 CAPLUS

DOCUMENT NUMBER: 146:45540

TITLE: Preparation of 1,2-di(cyclic) substituted benzene compounds as cell adhesion and cell infiltration inhibitors

INVENTOR(S): Kawahara, Tetsuya; Kotake, Makoto; Yoneda, Naoki; Hirota, Shinsuke; Ohkuro, Masayoshi

PATENT ASSIGNEE(S): Eisai R&D Management Co., Ltd., Japan

SOURCE: U.S. Pat. Appl. Publ., 313pp., Cont.-in-part of U.S. Ser. No. 453,194.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006276465	A1	20061207	US 2006-474225	20060623
US 2005261291	A1	20051124	US 2004-22702	20041227
US 2006281747	A1	20061214	US 2006-453194	20060614
WO 2006134955	A1	20061221	WO 2006-JP311900	20060614

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:
JP 2003-434312 A 20031226
JP 2003-435050 A 20031226
US 2004-22702 A2 20041227
JP 2005-174072 A 20050614
US 2006-453194 A2 20060614

OTHER SOURCE(S): MARPAT 146:45540
GI



AB The title compds. I [R10 = (un)substituted 5-10 membered cycloalkyl or

Erich Leeser

5-10 membered cycloalkenyl; R20-R23 = H, OH, halo, CN, etc.; R30-R32 = H, OH, halo, alkyl, etc.; or two of R30, R31 and R32 bond together to form oxo or methylene and the other represents H, OH, halo, etc.; R40 = (un)substituted alkyl, cycloalkyl, 4-8 membered heterocyclyl, etc.; n = 0-2; X1 = CH or N], were prepared. Thus, 1-[2-(4,4-dimethylcyclohexyl)-5-methoxyphenyl]-4-pentylpiperazine hydrochloride was prepared in a multistep process starting with 4,4-dimethylcyclohexanone. In an in vitro test for cell adhesion inhibiting activity using Jurkat cells, compds. of this invention showed IC50 values of 2.2 μ M to 7.7 μ M.

IT 916315-26-9P 916315-28-1P 916315-35-0P
 916315-36-1P 916315-37-2P 916315-41-8P
 916315-42-9P 916315-43-0P 916315-44-1P
 916315-45-2P 916315-48-5P 916315-49-6P
 916315-50-9P 916315-51-0P 916315-68-9P
 916315-69-0P 916315-70-3P 916315-71-4P
 916315-72-5P 916315-73-6P 916315-82-7P
 916315-83-8P 916315-84-9P 916315-85-0P
 916315-86-1P 916315-87-2P 916315-88-3P
 916315-89-4P 916315-90-7P 916315-91-8P
 916315-92-9P 916315-93-0P 916315-94-1P
 916315-95-2P 916315-96-3P 916315-97-4P
 916316-01-3P 916316-02-4P 916316-03-5P
 916316-04-6P 916316-05-7P 916316-06-8P
 916316-07-9P 916316-08-0P 916316-09-1P
 916316-10-4P 916316-13-7P 916316-15-9P
 916316-23-9P 916316-25-1P 916316-27-3P
 916316-29-5P 916316-31-9P 916316-33-1P
 916316-35-3P 916316-37-5P 916316-39-7P
 916316-45-5P 916316-47-7P 916316-49-9P
 916316-51-3P 916316-53-5P 916316-54-6P
 916316-61-5P 916316-63-7P 916316-65-9P
 916316-67-1P 916316-68-2P 916316-69-3P
 916316-70-6P 916316-71-7P 916316-72-8P
 916316-73-9P 916316-74-0P 916316-75-1P
 916316-76-2P 916316-81-9P 916316-82-0P
 916316-83-1P 916316-84-2P 916316-85-3P
 916316-86-4P 916316-87-5P 916316-88-6P
 916316-89-7P 916316-91-1P 916316-94-4P
 916316-95-5P 916316-96-6P 916316-97-7P
 916316-98-8P 916317-03-8P 916317-05-0P
 916317-32-3P 916317-33-4P 916317-39-0P
 916317-52-7P 916317-55-0P 916317-56-1P
 916317-61-8P 916317-62-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,2-di(cyclic) substituted benzene compds. as cell adhesion and cell infiltration inhibitors)

RN 916315-26-9 CAPLUS


CN Piperazine, 1-[2-(4,4-diethylcyclohexyl)-4-[4-(methoxymethyl)-1-piperidinyl]phenyl]-4-propyl-, hydrochloride (1:1) (CA INDEX NAME)

50613257



RN 916315-28-1 CAPLUS


CN Ethanone, 1-[4-[4-(4-butyl-1-piperazinyl)-3-(4,4-dimethylcyclohexyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 916315-35-0 CAPLUS

CN Piperazine, 1-butyl-4-[5-(2-methoxyethoxy)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

50613257




● HCl

RN 916315-36-1 CAPLUS

CN Piperazine, 1-butyl-4-[2-(4,4-diethylcyclohexyl)-4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 916315-37-2 CAPLUS

CN Piperazine, 1-[4-(2-methoxyethoxy)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-4-propyl-, hydrochloride (1:1) (CA INDEX NAME)

Erich Leeser


50613257



● HCl

RN 916315-41-8 CAPLUS

CN Benzoic acid, 4-(4-propyl-1-piperazinyl)-3-(3,3,5,5-tetramethylcyclohexyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916315-42-9 CAPLUS


CN Morpholine, 4-[[4-(4-butyl-1-piperazinyl)-3-(3,3,5,5-tetramethylcyclohexyl)phenyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

50613257



RN 916315-43-0 CAPLUS

CN Piperazine, 1-butyl-4-[4-(methoxymethyl)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916315-44-1 CAPLUS

CN 1-Propanone, 1-[4-(4-butyl-1-piperazinyl)-3-(3,3,5,5-tetramethylcyclohexyl)phenyl]-3-methoxy-, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916315-45-2 CAPLUS

CN Piperazine, 1-butyl-4-[4-(3-methoxy-1-propyn-1-yl)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916315-48-5 CAPLUS


CN Piperazine, 1-(cyclopropylmethyl)-4-[2-(4,4-diethylcyclohexyl)-4-[4-(methoxymethyl)-1-piperidinyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

50613257



● HCl


RN 916315-49-6 CAPLUS
CN Acetic acid, 2-[[1-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]-4-piperidinyl]oxy]-, hydrochloride (1:1)
(CA INDEX NAME)



● HCl


RN 916315-50-9 CAPLUS
CN Piperazine, 1-butyl-4-[4-[4-(methoxymethyl)-1-piperidinyl]-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

50613257



RN 916315-51-0 CAPLUS

CN Piperazine, 1-butyl-4-[2-[4-(1,1-dimethylethyl)cyclohexyl]-5-(2-methoxyethoxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916315-68-9 CAPLUS

CN Piperazine, 1-[5-(2-methoxyethoxy)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-4-propyl-, hydrochloride (1:1) (CA INDEX NAME)

50613257




● HCl

RN 916315-69-0 CAPLUS

CN Piperazine, 1-[2-(4,4-diethylcyclohexyl)-4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]phenyl]-4-propyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 916315-70-3 CAPLUS

CN Piperazine, 1-(cyclopropylmethyl)-4-[2-(4,4-diethylcyclohexyl)-4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.

Erich Leeser

50613257




RN 916315-71-4 CAPLUS
CN Piperazine, 1-butyl-4-[4-(2-methoxyethoxy)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 916315-72-5 CAPLUS
CN Piperazine, 1-[4-(2-methoxyethoxy)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-4-(2-methylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916315-73-6 CAPLUS

CN Piperazine, 1-[4-(2-methoxyethoxy)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916315-82-7 CAPLUS

CN Benzoic acid, 4-[4-(cyclopropylmethyl)-1-piperazinyl]-3-(3,3,5,5-tetramethylcyclohexyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916315-83-8 CAPLUS

CN 1-Propanone, 3-methoxy-1-[4-(4-propyl-1-piperazinyl)-3-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 916315-84-9 CAPLUS

CN Morpholine, 4-[[4-(4-propyl-1-piperazinyl)-3-(3,3,5,5-tetramethylcyclohexyl)phenyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)

50613257




RN 916315-85-0 CAPLUS
 CN Morpholine, 4-[[4-[4-(cyclopropylmethyl)-1-piperazinyl]-3-(3,3,5,5-tetramethylcyclohexyl)phenyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 916315-86-1 CAPLUS
 CN Piperazine, 1-[4-(methoxymethyl)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-4-propyl-, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916315-87-2 CAPLUS

CN Piperazine, 1-(cyclopropylmethyl)-4-[4-(methoxymethyl)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916315-88-3 CAPLUS


CN Benzoic acid, 4-(4-butyl-1-piperazinyl)-3-(3,3,5,5-tetramethylcyclohexyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

50613257



● HCl


RN 916315-89-4 CAPLUS
CN Piperazine, 1-[4-(3-methoxy-1-propyn-1-yl)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-4-propyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 916315-90-7 CAPLUS
CN Piperazine, 1-(cyclopropylmethyl)-4-[4-(3-methoxy-1-propyn-1-yl)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

50613257




● HCl

RN 916315-91-8 CAPLUS
CN Benzoic acid, 3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 916315-92-9 CAPLUS
CN Benzoic acid, 3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]- (CA INDEX NAME)



RN 916315-93-0 CAPLUS
CN 4-Piperidinol, 1-[4-(4-butyl-1-piperazinyl)-5-[4-(1,1-dimethylethyl)cyclohexyl]-2-methoxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Erich Leeser

50613257



● HCl


RN 916315-94-1 CAPLUS
CN Benzoic acid, 2-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 916315-95-2 CAPLUS
CN Benzamide, 2-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]-N-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916315-96-3 CAPLUS


CN Benzoic acid, 4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 916315-97-4 CAPLUS

CN Benzoic acid, 4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 916316-01-3 CAPLUS

CN Benzamide, 2-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]-N-

Erich Leeser

50613257


ethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 916316-02-4 CAPLUS

CN Benzanide, 2-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]-
N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916316-03-5 CAPLUS

CN Methanone, [2-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]-4-morpholinyl-, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916316-04-6 CAPLUS


CN Benzamide, 2-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 916316-05-7 CAPLUS

CN Benzamide, 2-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]-N-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

Erich Leeser

50613257

RN 916316-06-8 CAPLUS


CN Benzeneacetamide, 2-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]-N-ethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 916316-07-9 CAPLUS

CN Benzamide, 3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916316-08-0 CAPLUS

CN Benzamide, 3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916316-09-1 CAPLUS

CN Benzamide, 3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]-N-(2-methoxyethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916316-10-4 CAPLUS


CN Methanone, [3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]-4-morpholinyl-, hydrochloride (1:1) (CA INDEX NAME)

50613257



● HCl


RN 916316-13-7 CAPLUS
CN Acetamide, 2-[3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]phenoxy]-N-ethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 916316-15-9 CAPLUS
CN Acetamide, 2-[3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]phenoxy]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916316-23-9 CAPLUS

CN 2-Piperidinone, 1-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916316-25-1 CAPLUS


CN 2,6-Piperidinedione, 1-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

50613257




● HCl

RN 916316-27-3 CAPLUS
CN Benzenepropanamide, 3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 916316-29-5 CAPLUS
CN Benzenepropanamide, 3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]-N-ethyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

Erich Leeser

50613257

RN 916316-31-9 CAPLUS


CN Benzenepropanamide, 3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]-N,N-diethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 916316-33-1 CAPLUS

CN Ethanamine, 2-[3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]phenoxy]-N,N-diethyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 916316-35-3 CAPLUS

CN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[4-(4-butyl-1-piperazinyl)-5-[4-(1,1-dimethylethyl)cyclohexyl]-2-methoxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916316-37-5 CAPLUS

CN 4-Piperidinone, 1-[4-(4-butyl-1-piperazinyl)-5-[4-(1,1-dimethylethyl)cyclohexyl]-2-methoxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 916316-39-7 CAPLUS

CN Acetic acid, 2-[[1-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]-4-piperidinyl]oxy]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)

50613257




RN 916316-45-5 CAPLUS
CN Acetamide, 2-[[1-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]-4-piperidinyl]oxy]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)




RN 916316-47-7 CAPLUS
CN Acetonitrile, 2-[3-(4-propyl-1-piperazinyl)-4-(3,3,5,5-tetramethylcyclohexyl)phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)

50613257



● HCl


RN 916316-49-9 CAPLUS
CN Acetonitrile, 2-[3-(4-butyl-1-piperazinyl)-4-(3,3,5,5-tetramethylcyclohexyl)phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 916316-51-3 CAPLUS
CN Phenol, 3-(4-butyl-1-piperazinyl)-4-(3,3,5,5-tetramethylcyclohexyl)-, 1-methanesulfonate, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916316-53-5 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 3-[4-(cyclopropylmethyl)-1-piperazinyl]-4-(3,3,5,5-tetramethylcyclohexyl)phenyl ester (CA INDEX NAME)




RN 916316-54-6 CAPLUS

CN 1-Propanone, 1-[4-[4-(cyclopropylmethyl)-1-piperazinyl]-3-(3,3,5,5-tetramethylcyclohexyl)phenyl]-3-methoxy-, hydrochloride (1:1) (CA INDEX NAME)


Erich Leeser

50613257



● HCl


RN 916316-61-5 CAPLUS
CN Piperazine, 1-(cyclopropylmethyl)-4-[3'-methoxy-4-(3,3,5,5-tetramethylcyclohexyl)[1,1'-biphenyl]-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 916316-63-7 CAPLUS
CN [1,1'-Biphenyl]-3-carbonitrile, 3'-[4-(cyclopropylmethyl)-1-piperazinyl]-4'-(3,3,5,5-tetramethylcyclohexyl)-, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916316-65-9 CAPLUS

CN Piperazine, 1-(cyclopropylmethyl)-4-[5-(2-methoxyethoxy)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916316-67-1 CAPLUS


CN Piperazine, 1-butyl-4-[2-[4-(1,1-dimethylethyl)cyclohexyl]-5-(2-phenoxyethoxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

50613257




● HCl

RN 916316-68-2 CAPLUS
CN Piperazine, 1-butyl-4-[2-[4-(1,1-dimethylethyl)cyclohexyl]-5-[2-(2-methoxyethoxy)ethoxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 916316-69-3 CAPLUS
CN Benzenemethanol, 3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]- α,α -dimethyl-, hydrochloride (1:1)
(CA INDEX NAME)




● HCl

Erich Leeser

50613257


RN 916316-70-6 CAPLUS

CN 4-Piperidinamine, 1-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]-N,N-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)



RN 916316-71-7 CAPLUS


CN Thiomorpholine, 4-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]-, 1-oxide, hydrochloride (1:1) (CA INDEX NAME)



RN 916316-72-8 CAPLUS


CN Thiomorpholine, 4-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]-, 1,1-dioxide, hydrochloride (1:1) (CA INDEX NAME)

50613257



● HCl


RN 916316-73-9 CAPLUS
CN Thiomorpholine, 4-[4-(4-butyl-1-piperazinyl)-5-[4-(1,1-dimethylethyl)cyclohexyl]-2-methoxyphenyl]-, 1,1-dioxide, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 916316-74-0 CAPLUS
CN 2(1H)-Pyridinone, 6-[4-[4-(cyclopropylmethyl)-1-piperazinyl]-3-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

50613257



● HCl


RN 916316-75-1 CAPLUS
CN Piperazine, 1-[2,4-bis(3,3,5,5-tetramethylcyclohexyl)phenyl]-4-butyl-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 916316-76-2 CAPLUS
CN Piperazine, 1-propyl-4-[4-(3,3,5,5-tetramethyl-1-cyclohexen-1-yl)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916316-81-9 CAPLUS

CN Piperazine, 1-butyl-4-[2-[4-(1,1-dimethylethyl)cyclohexyl]-4-[4-(2-methoxyethoxy)-1-piperidinyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


MeO-CH₂-CH₂-O

RN 916316-82-0 CAPLUS

CN Acetonitrile, 2-[3-[4-(cyclopropylmethyl)-1-piperazinyl]-4-(3,3,5,5-tetramethylcyclohexyl)phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)

Erich Leeser


50613257



● HCl

RN 916316-83-1 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916316-84-2 CAPLUS

CN Piperazine, 1-(cyclopropylmethyl)-4-[5-phenoxy-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916316-85-3 CAPLUS

CN 1,4-Dioxa-8-azaspiro[4.5]decane, 8-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 916316-86-4 CAPLUS

CN 4-Piperidinone, 1-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]- (CA INDEX NAME)

50613257



RN 916316-87-5 CAPLUS
CN 4-Piperidinol, 1-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916316-88-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)


Erich Leeser

50613257



RN 916316-89-7 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 916316-91-1 CAPLUS

CN 2-Pyrrolidinone, 1-[4-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916316-94-4 CAPLUS

CN Piperazine, 1-butyl-4-[4-[4-(1,1-dimethylethyl)cyclohexyl][1,1'-biphenyl]-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 916316-95-5 CAPLUS

CN Piperazine, 1-[3'-methoxy-4-(3,3,5,5-tetramethylcyclohexyl)[1,1'-biphenyl]-3-yl]-4-propyl-, hydrochloride (1:1) (CA INDEX NAME)


50613257



● HCl

RN 916316-96-6 CAPLUS


CN [1,1'-Biphenyl]-3-carbonitrile, 3'-(4-propyl-1-piperazinyl)-4'-(3,3,5,5-tetramethylcyclohexyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 916316-97-7 CAPLUS

CN 2-Propenoic acid, 3-[3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

Erich Leeser

50613257


RN 916316-98-8 CAPLUS

CN 2-Propenoic acid, 3-[3-(4-butyl-1-piperazinyl)-4-[4-(1,1-dimethylethyl)cyclohexyl]phenyl]- (CA INDEX NAME)



RN 916317-03-8 CAPLUS


CN Piperazine, 1-[2-(4,4-diethylcyclohexyl)-4-[4-(methoxymethyl)-1-piperidinyl]phenyl]-4-propyl- (CA INDEX NAME)



RN 916317-05-0 CAPLUS


CN Ethanone, 1-[4-[4-(4-butyl-1-piperazinyl)-3-(4,4-dimethylcyclohexyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)

50613257



RN 916317-32-3 CAPLUS

CN Piperazine, 1-butyl-4-[5-(2-methoxyethoxy)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]- (CA INDEX NAME)




RN 916317-33-4 CAPLUS

CN Piperazine, 1-butyl-4-[2-(4,4-diethylcyclohexyl)-4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.

50613257




RN 916317-39-0 CAPLUS

CN Piperazine, 1-[4-(2-methoxyethoxy)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-4-propyl- (CA INDEX NAME)



RN 916317-52-7 CAPLUS

CN Benzoic acid, 4-(4-propyl-1-piperazinyl)-3-(3,3,5,5-tetramethylcyclohexyl)-, methyl ester (CA INDEX NAME)




Erich Leeser

50613257


RN 916317-55-0 CAPLUS

CN Morpholine, 4-[[4-(4-butyl-1-piperazinyl)-3-(3,3,5,5-tetramethylcyclohexyl)phenyl]methyl]- (CA INDEX NAME)



RN 916317-56-1 CAPLUS


CN Piperazine, 1-butyl-4-[4-(methoxymethyl)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]- (CA INDEX NAME)



RN 916317-61-8 CAPLUS


CN 1-Propanone, 1-[4-(4-butyl-1-piperazinyl)-3-(3,3,5,5-tetramethylcyclohexyl)phenyl]-3-methoxy- (CA INDEX NAME)

50613257



RN 916317-62-9 CAPLUS

CN Piperazine, 1-butyl-4-[4-(3-methoxy-1-propyn-1-yl)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]- (CA INDEX NAME)



IT 916317-02-7P 916317-09-4P 916317-11-8P
916317-13-0P 916317-14-1P 916317-28-7P
916317-30-1P 916317-35-6P 916317-36-7P
916317-48-1P 916317-49-2P 916317-51-6P
916317-53-8P 916317-54-9P 916317-57-2P
916317-58-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1,2-di(cyclic) substituted benzene compds. as cell adhesion and cell infiltration inhibitors)


RN 916317-02-7 CAPLUS

CN Piperazine, 1-[4-bromo-2-(4,4-diethylcyclohexyl)phenyl]-4-propyl- (CA INDEX NAME)


50613257



RN 916317-09-4 CAPLUS
CN Piperazine, 1-butyl-4-[2-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]-5-nitrophenyl]- (CA INDEX NAME)




RN 916317-11-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]-6-nitrophenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 916317-13-0 CAPLUS
CN Piperazine, 1-butyl-4-[2-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]-6-nitrophenyl]- (CA INDEX NAME)

Erich Leeser


50613257



RN. 916317-14-1 CAPLUS
CN Benzenamine, 2-(4-butyl-1-piperazinyl)-3-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]- (CA INDEX NAME)



RN 916317-28-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[5-(2-methoxyethoxy)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 916317-30-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-(4,4-diethylcyclohexyl)-4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.


Erich Leeser

50613257



RN 916317-35-6 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[4-hydroxy-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 916317-36-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[4-(2-methoxyethoxy)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

50613257




RN 916317-48-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-(methoxycarbonyl)-2-(3,3,5,5-tetramethyl-1-cyclohexen-1-yl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 916317-49-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-(methoxycarbonyl)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




Erich Leeser

50613257


RN 916317-51-6 CAPLUS

CN Benzoic acid, 4-(4-butyl-1-piperazinyl)-3-(3,3,5,5-tetramethylcyclohexyl)-
, methyl ester (CA INDEX NAME)




RN 916317-53-8 CAPLUS

CN Benzoic acid, 4-(4-butyl-1-piperazinyl)-3-(3,3,5,5-tetramethylcyclohexyl)-
(CA INDEX NAME)



RN 916317-54-9 CAPLUS

CN Methanone, [4-(4-butyl-1-piperazinyl)-3-(3,3,5,5-tetramethylcyclohexyl)phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 916317-57-2 CAPLUS

Erich Leeser


50613257

CN Benzenemethanol, 4-(4-butyl-1-piperazinyl)-3-(3,3,5,5-tetramethylcyclohexyl)- (CA INDEX NAME)



RN 916317-58-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-(3-methoxy-1-propyn-1-yl)-2-(3,3,5,5-tetramethylcyclohexyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1263063 CAPLUS

DOCUMENT NUMBER: 146:183987

TITLE: A sterically bulky cyclic thiourea as an efficient ligand for palladium-catalyzed aerobic oxidation of alcohols

AUTHOR(S): Yang, Min; Yip, Kai-Tai; Pan, Jie-Hui; Chen, Ying-Chun; Zhu, Nian-Yong; Yang, Dan

CORPORATE SOURCE: Department of Chemistry, The University of Hong Kong, Hong Kong, Peop. Rep. China

SOURCE: Synlett (2006), (18), 3057-3060

CODEN: SYNLES; ISSN: 0936-5214

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 1,3-Bis(2,5-di-tert-butylphenyl)-2-imidazolidinethione was demonstrated as an efficient ligand in palladium-catalyzed oxidation of alcs. using mol.

Erich Leeser

50613257

oxygen as an oxidant. This new catalyst system was applied to a wide variety of substrates such as benzylic alcs., aliphatic secondary alcs., and allylic alcs., producing the corresponding carbonyl compds. in good to excellent yields.


IT 921197-59-3P

RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation);
USES (Uses)

((tert-butylphenyl)imidazolidinethione as ligand for
palladium-catalyzed aerobic oxidation of alcs.)

RN 921197-59-3 CAPLUS

CN 2-Imidazolidinethione, 1,3-bis[4,4'-bis(1,1-dimethylethyl)[1,1'-biphenyl]-
2-yl]- (CA INDEX NAME)



REFERENCE COUNT:

40

THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1209633 CAPLUS

DOCUMENT NUMBER: 146:142273

TITLE: Lewis Base Activation of Grignard Reagents with
N-Heterocyclic Carbenes. Cu-Free Catalytic
Enantioselective Additions to γ -Chloro-
 α,β -Unsaturated Esters

AUTHOR(S): Lee, Yunmi; Hoveyda, Amir H.
CORPORATE SOURCE: Department of Chemistry, Merkert Chemistry Center,
Boston College, Chestnut Hill, MA, 02467, USA

SOURCE: Journal of the American Chemical Society (2006),
128(49), 15604-15605

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Direct activation of alkylmagnesium halides with a chiral bidentate
N-heterocyclic carbene (NHC), formed in situ from the imidazolinium
chloride precursor, is reported. The Cu-free catalytic asym. allylic
alkylation of α -alkyl- γ -chloro- α,β -unsatd. esters
with alkyl-based Grignard reagents is promoted in the presence of 5-10 mol
% of the chiral imidazolinium salt to afford synthetically versatile
 β,γ -unsatd. esters. Products bear all-carbon quaternary
stereogenic centers generated in 3.5-13.3:1 regioselectivity, 63-98% ee,
and in up to 80% isolated yield of the SN2' product. The
in-situ-generated chiral NHC promotes enantioselectivity while altering

Erich Leeser

50613257

the reactivity of the Grignard reagents: there is only .apprx.30% conversion and <2% allylic alkylation in the absence of chiral carbene.

IT 919087-63-1P 919087-64-2P


RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)

(asym. allylic alkylation of α -alkyl- γ -chloro- α,β -unsatd. esters with Grignard reagents and a chiral imidazolium catalyst)

RN 919087-63-1 CAPLUS

CN 1H-Imidazolium, 1-[1,1'-biphenyl]-2-yl-4,5-dihydro-4,5-diphenyl-3-(2,4,6-trimethylphenyl)-, chloride (1:1), (4S,5S)- (CA INDEX NAME)

Absolute stereochemistry.



● Cl⁻


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 919087-64-2 CAPLUS

CN 1H-Imidazolium, 4,5-dihydro-1-(2'-methoxy[1,1'-biphenyl]-2-yl)-4,5-diphenyl-3-(2,4,6-trimethylphenyl)-, chloride (1:1), (4S,5S)- (CA INDEX NAME)

Absolute stereochemistry.

50613257



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:840567 CAPLUS

DOCUMENT NUMBER: 145:397590

TITLE: Activity of Nitrogen-Containing and
Non-Nitrogen-Containing Bisphosphonates on Tumor Cell
Lines

AUTHOR(S): Zhang, Yonghui; Leon, Annette; Song, Yongcheng;
Studer, Danielle; Haase, Christa; Koscielski, Lukasz
A.; Oldfield, Eric

CORPORATE SOURCE: Department of Chemistry, University of Illinois at
Urbana-Champaign, Urbana, IL, 61801, USA

SOURCE: Journal of Medicinal Chemistry (2006), 49(19),
5804-5814

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:397590

AB Arylethylidene-, pyridiniumethylidene- and 1-hydroxyethylidene-
bis-phosphonates were prepared by bis-phosphonylation of the corresponding
carboxylic acids, alkylation of methylenebis(phosphonate) by substituted
benzyl halides or addition of vinylidenebis(phosphonates) with substituted
pyridines. The activity of the prepared bis-phosphonates in inhibiting the
growth of three human tumor cell lines, MCF-7 (breast), NCI-H460 (lung),
and SF-268 (CNS) was evaluated. The first series of compds. consisted of
49 2-(pyridinio)ethylidene-1,1-bisphosphonates the most active species
being a tetrakis-pivaloyloxymethyl (POM) ester, having an average IC₅₀ of 6.8
μM. The second series of compds. consisted of nine 2-(terphenyl)
ethylidene-1,1-bisphosphonates, the most active species also being a POM
ester, having an IC₅₀ of 2.2 μM. The third series of compds. consisted
of seven halogen- or cyano-substituted 2-phenylethylidene-1,1-
bisphosphonates, the most active species again being a POM ester, having
an IC₅₀ of 500 nM. The prepared bisphosphonate esters can have potent
activity against a variety of tumor cell lines, with the most active

terphenyl- and halophenyl-containing species having IC50 values
 .apprx.10-40+ lower than the most potent com. available
 bisphosphonates.

IT 911496-93-0P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (preparation of pyridinio-, biphenyl- and 1-hydroxyethylidene
 bis-phosphonates as growth inhibitory agents for human tumor cell
 lines)
 RN 911496-93-0 CAPLUS
 CN Pyridinium, 4-[1,1'-biphenyl]-2-yl-1-(2,2-diphosphonoethyl)-, inner salt
 (9CI) (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:753456 CAPLUS

DOCUMENT NUMBER: 145:356907

TITLE: Rearrangement of N-Heterocyclic Carbenes Involving
 Heterocycle Cleavage

AUTHOR(S): Waltman, Andrew W.; Ritter, Tobias; Grubbs, Robert H.

CORPORATE SOURCE: Division of Chemistry and Chemical Engineering,
 California Institute of Technology, Pasadena, CA,
 91125, USA

SOURCE: Organometallics (2006), 25(18), 4238-4239

CODEN: ORGND7; ISSN: 0276-7333

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In two similar but unrelated cases, a novel type of ring-opening reaction
 of N-heterocyclic carbenes (NHCs) was observed. These compds. may represent a
 general class of hitherto unknown decomposition products of NHCs. Thus,
 ring-expansion reaction of 1-(2,6-diisopropylphenyl)-3-(2-hydroxy-3-
 (adamant-1-yl)-5-methylphenyl)-4,5-dihydroimidazolium chloride with
 potassium hexamethyldisilazide in THF followed by treatment with
 NiClPh(PPh3)2 in THF gave 59% N-(2,6-diisopropylphenyl)-N-benzylidene-N'-
 (2-hydroxy-3-(adamant-1-yl)-5-methylphenyl)ethylenediimine
 triphenylphosphine nickel(II) complex (crystal structure).

IT 910482-27-8P 910482-28-9P 910482-33-6P
 910482-34-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(rearrangement of N-heterocyclic carbenes involving heterocycle cleavage
 or ring-expansion and structural characterization of products)

RN 910482-27-8 CAPLUS

CN 1H-Imidazolium, 4,5-dihydro-1-(2'-iodo-6,6'-dimethyl[1,1'-biphenyl]-2-yl)-
 3-(2,4,6-trimethylphenyl)-, chloride (9CI) (CA INDEX NAME)

50613257




● Cl⁻

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 910482-28-9 CAPLUS

CN Imidazolidine-2-d, 1-(2'-iodo-6,6'-dimethyl[1,1'-biphenyl]-2-yl)-2-(trichloromethyl)-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 910482-33-6 CAPLUS


CN Imidazolidine, 1-(2'-iodo-6,6'-dimethyl[1,1'-biphenyl]-2-yl)-2-(trichloromethyl)-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)

Erich Leeser

50613257



RN 910482-34-7 CAPLUS
CN Imidazolidine-2-d, 1-(2'-iodo-6,6'-dimethyl[1,1'-biphenyl]-2-yl)-2-(trichloromethyl-¹³C)-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

18

THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT